Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:QLGN
DateTimeSourceHeadlineSymbolCompany
30/05/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
30/05/202421:00GlobeNewswire Inc.Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting DeterminationNASDAQ:QLGNQualigen Therapeutics Inc
14/05/202421:05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:QLGNQualigen Therapeutics Inc
04/05/202401:59Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
16/04/202412:00GlobeNewswire Inc.Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™NASDAQ:QLGNQualigen Therapeutics Inc
10/04/202413:00GlobeNewswire Inc.Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
09/04/202413:00GlobeNewswire Inc.Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
27/02/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
22/02/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/12/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
22/11/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
14/11/202321:30GlobeNewswire Inc.Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/11/202319:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/11/202313:30GlobeNewswire Inc.Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
23/10/202313:30GlobeNewswire Inc.Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerNASDAQ:QLGNQualigen Therapeutics Inc
17/10/202313:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
28/09/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
27/09/202313:30GlobeNewswire Inc.Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/09/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QLGNQualigen Therapeutics Inc
01/09/202321:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:QLGNQualigen Therapeutics Inc
17/08/202313:30GlobeNewswire Inc.Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
15/08/202315:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
15/08/202313:30GlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023NASDAQ:QLGNQualigen Therapeutics Inc
14/08/202321:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QLGNQualigen Therapeutics Inc
04/08/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
01/08/202313:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
01/08/202313:30GlobeNewswire Inc.Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
26/07/202322:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
24/07/202313:15GlobeNewswire Inc.Qualigen Therapeutics Divests FastPack® Diagnostics BusinessNASDAQ:QLGNQualigen Therapeutics Inc
13/07/202322:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QLGN